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Abstract
Splenic marginal zone lymphomas (SMZL) are an uncommon type of B-cell non-Hodgkin’s lymphoma (NHL-B) in which no
specific chromosomal translocations have been described. In contrast, the most frequent cytogenetic abnormality is the loss
of the long arm of chromosome 7 (7q). Previous reports have located this loss in the 7q32 region. In order to better
characterize the genomic imbalances in SMZL, molecular studies were carried out in 73 patients with SMZL. To gain insight
into the mapping at 7q a tiling array was also used. The results confirmed the loss of 7q as the most frequent change. In
addition, several abnormalities, including 4q22.1, 1q21.3–q22, 6q25.3, 20q13.33, 3q28, 2q23.3–q24.1 and 17p13, were also
present. A loss of 7q22.1 at 99925039–101348479 bp was observed in half of the cases. The region of 7q22.1 has not
previously been characterised in SMZL. Our results confirmed the presence of a new region of loss on chromosome 7 in
these NHL.
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Introduction
Splenic marginal zone lymphomas (SMZL) are low-grade B-cell
lymphomas with a micronodular pattern of spleen involvement,
occupyingthemarginalzone[1].IntheRevisedEuropean-American
Classification of Lymphoid Neoplasm (REAL), SMZL is considered
as a provisional entity, and is included with marginal zone lymphoma
of mucosa-associated lymphoid tissue (MALT) type and nodal
marginal zone lymphoma in the class of marginal zone lymphomas
[2]. However, in the World Health Organization classification,
SMZL is regarded as a separate entity [3]. SMZL accounts for fewer
than 1% of the non-Hodgkin’s B-cell lymphomas (NHL-B).
Cytogenetic abnormalities are commonly present in SMZLs.
The most frequent of these are deletions on 7q (30–40%) and gains
of 3q (20–30%) and 12q (15–20%). Complex chromosomal
imbalances are also common [4]. Losses on 7q mainly involve
band 7q32, although distinct regions of loss located either
centromerically or telomerically to this region have also been
identified [5–12]. Upon analyzing SMZL by means of chromo-
some-based comparative genomic hybridization (CGH) the most
frequent chromosomal numerical imbalances proved to be gains of
3q (25%), 5q (28%), 9q (21%), 12q and 20q (22%), and losses of 7q
(25%), 6q (20%), 14q (10%), and 17p (10%) [5,13–16]. Using
interphase fluorescence in situ hybridization (FISH), microsatellite
LOH analysis, and chromosome-based CGH analysis, several
studies have mapped the common region of the 7q deletion in
SMZL to 11.4 Mb at 7q31.3–7q33 [9,17]. By contrast, the
information about the presence of gains and losses of chromo-
somes obtained from array-based comparative genomic hybrid-
ization (CGH arrays) is scarce and comprised only of small series.
These have not contributed to the further delineation of the
minimal common region of the 7q deletion [18–21].
In the present study, a large series of SMZL was analyzed by
CGH arrays, followed by a high-resolution chromosome 7 tiling
array. The results were confirmed by molecular studies, to
characterize the minimal common region of the 7q deletion.
Our results identify new regions involved in this disease, and




A total of 73 samples of SMZL were analyzed. Sixty-eight
samples were assayed by BAC CGH array and those regions
affected by genomic imbalances were annotated for each case.
Most of the patients (84%) showed genomic changes. The median
number of changes per patient was four (with a range from 0 to
12). The most frequent changes were chromosomal gains involving
4q22.1 (14/57; 25% of patients), 1q21.3–q22 (12/57; 21%),
PLoS ONE | www.plosone.org 1 September 2011 | Volume 6 | Issue 9 | e249396q25.3 (11/57; 19%), 20q13.33 (11/57; 19%), 3q28 (10/57; 18%),
22q (10/57; 18%), 6p21.1 (8/57; 14%), and 11q12.2 (8/57; 14%)
while the genomic losses were located on 7q22.1 (28/57; 49%),
2q23.3–q24.1 (20/57; 35%), 17p13.3–p13.1 (18/57; 32%),
4q31.3–q32.1 (17/57; 30%), 7q31–q35 (17/57; 30%), 3p26.1
(14/57; 25%), 3q13.11 (13/57; 23%) and 18q12.1 (9/57; 16%)
(Fig. 1). The analysis performed by BAC CGH array in SMZL did
not identify any homozygous loss in the 7q22.1 region.
Oligonucleotide CGH array
In addition to the FISH studies, an oligonucleotide CGH arrays
analysis was carried out in a group of 19 SMZLs from the global
series. Overall, the results provided by the two platforms used
confirmed the BAC CGH array results. Thus, alterations such as
gains on chromosomes 3, 5q13.2, 6p22.1–p21.1, 8q, 17q and 18,
and losses in 4q28.3–q31.23, 10q24.33–q25.3, 15q15.1–q21.1 and
17p13.3–p13.1 were observed with the three CGH array methods.
FISH validation of losses identified by BAC CGH array
To confirm the genetic imbalances on 7q revealed by BAC
CGH array, FISH experiments were carried out in a total of 20
patients. In all cases FISH analysis confirmed the BAC CGH array
results. For this purpose, FISH studies in twelve patients, seven of
whom had losses in 7q revealed by BAC CGH array and five who
had no genetic imbalances in 7q, were performed. FISH
confirmed the losses on 7q22.1 previously assessed by BAC
CGH array (Table 1). FISH analysis of the 7q33.1 region was
performed in eight cases, six of which showed loss of this region
with BAC CGH array and FISH studies confirmed the presence of
one hybridization signal in these cases. The remaining two cases
did not show 7q33.1 abnormalities with either the BAC CGH
array or FISH.
High-resolution analysis of chromosome 7q
Interestingly, BAC CGH arrays detected two regions of losses
on chromosome 7q (Fig. 2). One of the regions was located in the
cytoband 7q22.1 and was deleted in 49% of patients with SMZL.
This region was 1.51 Mb long, located between the BAC clones
bA44M6 and bA333G13. The second region was larger, and
localized between the 7q31 and 7q35 cytobands. This region was
43.15 Mb in size and situated between the BAC clones bA5N18
(7q31.1) and dJ558L10 (7q35). This second region was less
frequent, affecting 30% of SMZL patients, and was located on
7q31–q35. In addition, one patient showed a deletion of only the
7q32 region.
Chromosome 7 tiling-array analysis enabled the boundaries of
rearrangements found by CGH array to be refined. Chromosome
7 tiling array NimbleGen 385K was used in four SMZL patients.
We found three patients with losses on band 7q22.1, where genes
such as MUC3, MUC12 and CUX1 were localized. This focused
array was used to obtain a better analysis of the deleted region on
7q. Figure 3 A shows a probe-level view of (A) the BAC CGH
array, (B) the CGH array NimbleGen 385K and (C) illustrate the
detail of the area of the deletion (7q22.1). The focused array has
more probes covering the same genomic area, so it enables a better
and more accurate estimate of the exact break-point boundaries
compared with the whole-genome array.
Determination of the commonly lost region on
chromosome 7
We analyzed the extent of the region identified on 7q22.1 by the
CGH array and tried to define the minimum region of molecular
allelic loss. Nine markers were analyzed in six patients with SMZL.
The chosen markers have been described in previously published
Figure 1. The commonest regions of genomic imbalances as
revealed by CGH arrays in splenic marginal zone lymphoma
(SMZL). The tree shows the chromosomal regions that exhibited gains
(right) or losses (left). For each region, a corresponding cytogenetic
location and the respective frequency of change within the cohort are
provided.
doi:10.1371/journal.pone.0024939.g001
Table 1. BAC Clones located in the 7q22.1 region.
BAC clone Position (bp) FISH Alteration BAC CGH array
Start End
bA506M12 99507535 99508053 No data Normal
bA44M6 99873610 100038722 Loss Loss
dJ1059M17 100976355 101150307 No data Loss
bA333G13 101175494 101390682 Loss Loss
bA401L13 102514284 102705988 No data Normal
doi:10.1371/journal.pone.0024939.t001
Loss on 7q22.1 in SMZL
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patients analyzed (67%) showed LOH on various markers
analyzed on chromosome 7. Likewise, the LOH revealed that
the markers D7S662, D7S2536 and D7S515, located at
100950585, 101235892 and 101490495, had losses of 50%, 20%
and 60%, respectively (Fig. 4). Therefore, based on the analysis of
the CGH array and LOH, the region commonly lost in SMZL is
located between 99925039 and 101348479 bp (Fig. 5).
Discussion
The present study assessed DNA copy number alterations in
SMZL by using a CGH array and refined the region lost at 7q. In
addition to the previous region located at 7q32, the results showed
the presence of another small lost region located on 7q22.1.
Previous studies using chromosome banding, FISH, LOH,
chromosomal-based CGH and oligonucleotide CGH arrays have
Figure 2. BAC CGH array analysis of chromosome 7 from 68 patients with SMZL. Each patient is shown in columns while the location of the
BAC clones is shown in rows. Red colour indicates the presence of a loss, while green indicates a gain of genomic material. Yellow represents a
normal amount of DNA, and blue indicates a deficient hybridization. The common deleted region on 7q22.1 is shown in a red box.
doi:10.1371/journal.pone.0024939.g002
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a recurrent abnormality in SMZL [5,6,12,13,17–21,24,25].
CGH array results from three different platforms confirmed that
partial loss of 7q is among the most frequent imbalances in SMZL.
It should be noted that this deletion was precisely delimited in two
regions: 7q22.1 with 1.51 Mb size and another well-known region
from 7q31 to 7q35 spanning 43.15 Mb. Interestingly, we found
the deletion on 7q22.1 by BAC array in 49% of the SMZL
samples. This region has usually been out of the lost region on 7q
in most of the previous studies [5,6,11,13,19,20,26–29]. In our
study the BAC CGH array approach, with a resolution of 1 Mb,
showed that the deletion on 7q22.1 was delimited by two BAC
clones, bA44M6 and bA333G13, and involved MUC3, MUC12
and CUX1 genes. This recurrent abnormality suggests that this
region may contain genes involved in SMZL that are yet to be
identified. The genes of the MUC family, which includes MUC3
and MUC12, code for transmembrane mucins, and are involved in
epithelial cell protection, adhesion modulation, and signalling;
their aberrant expression could be associated with human cancers
[30,31]. The protein encoded by the CUX1 gene is a member of
Figure 3. Detailed analysis of the commonly deleted region at 7q22.1 by use of two different CGH arrays. Three cases showed loss in
the region (43SMZL, 06SMZL and 14SMZL) between 99925039–101348479 bp (size 1.5 Mb), while the CGH array did not reveal any abnormality of
the 7q22.1 region in the control SMZL (18SMZL). (Red, losses; green, gains; yellow, normal; blue, non-informative oligonucleotide hybridization).
Figure 3C shows a close-up of a selected region, illustrating the loss on 7q22.1 in three SMZL patients.
doi:10.1371/journal.pone.0024939.g003
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regulate gene expression, morphogenesis and differentiation, and
may also play a role in cell-cycle progression. Moreover, it has a
function as a transcriptional repressor of the c-MYC proto-
oncogene. The chromosomal position and function of CUX1
suggest that it may act as a tumour-suppressor gene [22]. This
gene regulates normal B lymphopoiesis, and its alteration is
associated with lymphoid abnormalities in mice [32,33]. Aberrant
expression of CUX1 could be related to tumour progression in a
number of cancers [22,23,34–40], but to date studies of SMZL
have not demonstrated any relationship between CUX1 and this
NHL.
In a previous study, 13 markers covering the region 7q21–7q36
were analyzed. The marker D7S487 located on 7q31.3 was
frequently lost (45%), while D7S518 (7q22.1) did not show LOH
in the cases analyzed [17]. Our study confirmed that the marker
D7S518 was heterozygous in all the patients analyzed. However, a
more detailed analysis of the 7q22.1 region showed LOH in
markers D7S527 (7q21.3; 2 patients), D7S662 (7q22.1; 2 patients),
D7S2536 (7q22.1; 1 patient) and D7S515 (7q22.1; 3 patients). It is
notable that two of the markers used in the LOH analysis are in
the CUX1 gene located in this region (7q22.1): CUX1 D7S515
(intron 3) and CUX1 D7S518 (intron 20) [22]. Therefore, the
LOH complements the findings obtained from the CGH array,
which revealed a frequent loss of genomic material in the 7q22.1
region. When we analyzed this region in greater depth, through
tiling arrays and LOH studies, it was possible to refine the
mapping of the region to Chr7: 99925039–101348479 bp.
CGH arrays showed a second region, located on 7q31–q35, that
has been found to be deleted in SMZL in previous studies
[5,6,12,13,17–21,25,24]. This region was 43.15 Mb in size,
ranging between the BAC clones bA5N18 and dJ558L10. In the
present study the region was lost in 30% of SMZL patients. This
anomaly is considered a relatively specific genetic marker of
SMZL and has been associated with an aggressive clinical course
[17]. The region includes genes such as THAP5, IMMP2L,
FOXP2, TES, MET, ST7, PTPRZ1, GRM8, UBE2H, MLKN1,
BPGM, CALD1, PTN, SVOPL, AGK, KEL, TPK1 and CNTNAP2.
The MET gene is a proto-oncogene and an important regulator of
cell proliferation and differentiation, organ regeneration, embryo-
genesis and oncogenesis. It may be one of the longest-sought
oncogenes controlling progression of primary cancers to metasta-
sis. By contrast, the ST7 gene is a tumour suppressor gene that is
underexpressed in mantle cell lymphoma [41].
In summary, the resolving power of the CGH array enabled us
to confirm that the most frequent alterations in SMZL were losses




Seventy-three patients with the diagnosis of SMZL were
studied. All cases were reviewed by expert haemopathologists
(TF, MM, MAP) and the diagnosis was established according to
the WHO classification [3,42,43] Forty of the patients (52%) were
women. The ages ranged from 44 to 86 years (median 69 years).
The study was approved by the local ethical committees ‘‘Comite ´
E ´tico de Investigacio ´n Clı ´nica, Hospital Universitario de Sala-
manca’’. Informed consent was obtained from each patient before
they entered the study.
Methods
Of the 73 patients with SMZL included in the study, 68 were
analyzed by BAC CGH arrays. To confirm the results from these,
commercial oligonucleotide microarrays were used in 19 of these
patients (a NimbleGen CGH array 72 k was used for 11 patients,
while the remaining eight were analyzed with an Agilent CGH
array 44 k). Four of the 68 cases were studied by tiling array. Six
cases were studied by LOH, five of which were not studied by
BAC CGH arrays. The array data has been deposited in the gene
expression omnibus database, the accession number is GSE31203.
DNA isolation
All genomic DNA was extracted from fresh-frozen samples
using the standard phenol-chloroform method. Tumour DNA was
isolated from the spleen (49 cases), peripheral blood (27 cases) or
bone marrow (3 cases). Of the 68 cases analyzed using the BAC
arrays, most (44 patients) were studied in spleen while the
remaining 24 were analyzed in PBL. In all samples the tumour cell
percentage was greater than 50%. Normal DNA was extracted
from the human placenta of healthy donors. All DNA was
quantified using a NanoDrop spectrophotometer (ND-1000,
NanoDrop Technologies, Wilmington, DE). DNA quality was
assessed by the 260:280 ratio and its integrity by agarose gel
ethidium bromide visualization [44].
CGH array studies
1. BAC CGH array. A genome-wide analysis of DNA copy
number changes of patients was performed using a BAC CGH
array. Slides containing 3528 BACs spanning the genome were
produced at the Cancer Research Centre (Salamanca, Spain) as
Figure 4. Mapping of LOH in region 7q. (Left) Representation of
human chromosome 7, including band assignments. (Right) Names of
polymorphic markers used and chromosome band assignments. Four of
the six patients analyzed (70, 71, 66 and 73) show LOH for one or more
of the markers included in the region 7q22.1 (D7S662, D7S2536,
D7S515).
doi:10.1371/journal.pone.0024939.g004
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of unamplified genomic DNA, test (tumour DNA) and reference
material (placental DNA) were digested separately with DpnII
restriction enzyme (New England Biolabs, Beverly, MA) and
separately labelled using random primers (BioPrime Labeling
System, Invitrogen, Carlsbad, Calif) and Cy5-dCTP and Cy3-
dCTP (CyDye
TM 3-dCTP and CyDye
TM 5-dCTP, Amersham
Biosciences, Piscataway, NJ) fluorescent dye for paired hybridization
samples, respectively. The incorporation of labelled nucleotide
was quantified using a NanoDrop spectrophotometer (ND-1000,
NanoDrop Technologies). Labelled testand reference DNA samples
were mixed equitably, co-precipitated in the presence of Cot-1
human DNA (Roche, Indianapolis, IN) with ethanol, washed, and
resuspended in hybridization solution (50% formamide, 10%
Dextran sulphate, 26standard saline citrate, 10 mM Tris pH 7.6,
2.7% sodium dodecyl sulphate and 10 mg/ml of yeast tRNA). DNA
mixtures werecohybridized tothe arraysina GENETAC (Genomic
Solutions, Ann Arbor, Michigan, USA) for 48 hours at 42uCi n
accordance with the manufacturer’s recommended protocol.
Images and signal intensities were acquired using a GenePix
4000B (Axon Instruments, Burlingame, CA) dual laser scanner in
combination with GenePix Pro4.0 (Axon Instruments, Burlingame,
CA) imaging software. Fluorescence ratios were normalized using
themedianof the fluorescenceratiosof everyspot,computed aslog2
values. The log2 ratio of each clone was normalized to the median
log2 ratio of the 20 controlhybridizations, after which the median of
the three spots was calculated. Data from two-colour hybridizations
for both sets of DNA were normalized using the DNMAD module
of the GEPAS software [46–48]. Regions of copy number gain and
loss for the BAC CGH array data were identified by creating
sample-specific thresholds [49]. A cut-off value of 0.4 was used,
based on the ratios of clones in ten hybridizations of normal male
versus normal female DNA [45]. The clones with log2 ratios above
orbelowa controlsample’sthresholdvalue wereconsidered asgains
or losses, respectively. At least two contiguous BAC clones with a
log2 ratio of 20.4 or less were defined as a region of loss and a log2
ratio of +0.4 or more was defined as a region of gain. Furthermore,
spots with weak Cy3 or Cy5 intensity (R
2,0.2) and clones with a
standard deviation of more than 0.3 from measurement of the three
spotswereexcludedfromtheanalysis.Approximately10%ofclones
were excluded in this way. All data sets were carefully reviewed for
frequently affected chromosomal sites of physiological copy number
polymorphisms (CNPs). Every clone on the array was compared
withthe‘DatabaseofGenomicVariants’(availableat: www.project.
tcag.ca/cariation; accessed November 2009) and that of chromo-
somal imbalances and phenotype in humans using Ensembl
Resources (DECIPHER: available at: http://www.sanger.ac.uk/
PostGenomics/decipher/; accessed November 2009) [49–51].
2. Oligonucleotide CGH array platforms. To confirm the
results from the BAC CGH array analysis, two types of oligonucleo-
tide CGH array platforms were used. Eight SMZLs were analyzed
with Agilent’s Human Genome CGH Microarray 44 k (Agilent
Figure 5. Genetic analysis combined in cytoband 7q22.1 in splenic marginal zone lymphoma. Each method used to analyze the 7q22.1
region commonly deleted in the SMZL is represented by a separate colour. The green boxes correspond to losses detected by BAC mapping to this
region; the blue, yellow and purple boxes represent the fragments of the chromosome 7q22.1 region in which losses were detected by commercial
NimbleGen arrays. Black boxes show the losses observed with LOH. White boxes define the position of the BAC clones, oligonucleotides and markers
of LOH that were not deleted in SMZL.
doi:10.1371/journal.pone.0024939.g005
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mer probes spaced at 43000 bp intervals throughout the human
genome and includes 3877 controls. The probes are, according to the
manufacturer’s description, enriched in cancer-relevant genes,
representing both coding and non-coding sequences on the
chromosomes. Experiments using Agilent arrays were performed
using human placenta genomic DNA as reference and following
Agilent’s recommended standard protocol. The arrays were scanned
using the Agilent scanner, and data were extracted, filtered and
normalized using the Feature Extraction program (Agilent
Technologies). The Agilent CGH Analytics Software 3.4 trial
(Agilent Technologies) was used to export the CGH array data for
use with Nexus Copy Number Professional trial software (version 4,
BioDiscovery Inc) [52].
Eleven patients with SMZL were analyzed with NimbleGen
human CGH 4672K Whole Genome v2.0 array (Roche
NimbleGen, Inc). Placenta DNA was used as the reference. The
CGH array protocol from NimbleGen Systems was followed.
Briefly, 500 ng of tumour and reference DNA were labelled with
Cy3 and Cy5, respectively. Labelled material was co-hybridized to
microarrays consisting of 71341 oligonucleotide probes spaced at
approximately 40000 bp intervals throughout the human genome,
washed and scanned at 10 mm resolution using the GenePix
4000B dual scanner (Axon Instruments, Burlingame, CA). Raw
data were extracted using NimbleScan software v2.5 (Roche
NimbleGen, Inc), which enables automated grid alignment,
extraction and generation of data files [53].
3. Detailed analysis of chromosome 7. Fluorescence in situ
hybridization (FISH) analysis. To confirm the losses identified by CGH
array, FISH analysis was performed using the BAC clones bA44M6
mapped to 7q22.1 (99873610–100038722 bp), bA333G13 mapped
to 7q22.1 (101175494–101390682 bp), bA36B6 mapped to7q31.31
(130078078–130270796 bp) and bA371N6 mapped to 7q33
(134684519–134842787 bp) as previously described (NCBI36/hg18)
[54]. These clones were selected from the same BAC CGH array
clones library used for the BAC CGH array studies (Wellcome Trust
Sanger Institute, Cambridge, UK). DNA from the BAC clones was
isolated and directly labelled with either Spectrum Green-dUTP or
Spectrum Orange-dUTP (Vysis/Abbott Molecular, Inc.) by nick
translation and hybridized as previously described [54]. All BAC
clones were first hybridized to normal human metaphase
chromosomes in order to verify their location. A minimum of 200
interphase nuclei were scored using an E1000 microscope (Nikon,
Tokyo, Japan) equipped with the Quips system (Vysis, Downers
Grove, IL).
Tiling CGH array. In order to localize the lost region at 7q better,
four patients with SMZL were analyzed using tiling-path CGH
arrays. These arrays were designed at higher resolution with fine-tiling
analysis of chromosome 7 (chromosome7:117711–158805222 bp).
This array was constructed by maskless array synthesis technology
(Roche NimbleGen, Inc.), with up to 385110 oligonucleotides, with a
median probe spacing of 365 bp, and synthesized by photolithogra-
phy on an array by previously described methods [55,56]. Arrays
were scanned at 5 mm resolution using the NimbleGen MS 200
Microarray scanner (Roche NimbleGen, Inc) data were extracted
from the scanned images using NimbleScan software v2.5 (Roche
NimbleGen, Inc) [53].
LOH analysis. DNA from patients was extracted from spleen and
peripheral blood or bone marrow tissues as previously described.
Seven microsatellite markers on chromosome7 were used (Table 2).
Four of these markers, D7S662, D7S2536, D7S515 and D7S518,
were used to define more precisely the level of the deleted region
7q22.1 detected in a high percentage of SMZLs. All microsatellite
markers were selected on the basis of their location (Genethon map
release, GDB and RHdb) and on the frequent LOH detected in
losses on 7q. PCR reactions were performed in a final volume of
25 ml containing approximately 30–50 ng/ml of template DNA, 56
PCR buffer, 2.5 mM dNTPs, 25 mM Mg2Cl, 10 mM of each
primer, and 1 U of Taq DNA polymerase (Promega, Madison, WI,
USA). PCR was performed in a thermal cycler. Amplification
consisted of an initial denaturing step of 5 min at 94uC, 35 cycles of
30 s at 94uC, 30 s at 55–65uC and 30 s at 72uC, followed by a final
step of 5 min at 72uC. The PCR products were separated by 3% of
agarose gel (MS4 Metagel, Conda).
Allelic loss was scored only for informative patients whose
normal DNA samples were polymorphic at a given locus. LOH
was identified by visual analysis as a loss in intensity or complete
loss of one allele in the tumour DNA when compared with the
normal DNA from the same patient. All cases of LOH were
agreed by three reviewers.
Table 2. Microsatellites markers selected for the LOH analysis.
Markers Region Chromosome Size (bp) Localization (bp) Sequence
D7S527 7q21.3 273–297 95453048 Forward CATTGCAAACTCAGGAGATA
Reverse TAACAGAGGCATGAAAACCA
D7S662 7q22.1 204–234 100950585 Forward GTTGACAGACAAGCACAGAC
Reverse AGCTGTTTCCCATTTCCA
D7S2536 7q22.1 118–141 101235892 Forward ACACTCCGCCACCTTG
Reverse CAACAACTGTTCCTAAAGCCT
D7S515 7q22.1 128–190 101490495 Forward GGGAGTTACTACCCTCACTTAATG
Reverse GGACTGGGCAGCAAAG
D7S518 7q22.1 179–201 101648938 Forward CAGTAGGCAGGGGTGG
Reverse GGGTGTGTCTGTGTGACAAC
D7S500 7q33 188–210 134759259 Forward CCAGAATTGAAAACTCAGCA
Reverse ATTGATTGAGGAACTGAACTTACCT
D7S550 7q36.3 177–200 155210270 Forward TCTCATCTGTGAATGCACTATC
Reverse GCAGTTGGGTTATTTCAAGTC
doi:10.1371/journal.pone.0024939.t002
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